The inhibition of VEGF reduced microvessel number and led to the increase of hypertension incidence during anti-cancer therapy, whereas enhancing the activity of endogenous VEGF by intramuscular local or systemic injection of small VEGF-binding peptide under hind limb ischemia and wound conditions is a common strategy to increase angiogenesis in vivo [19]. This evidence concerns the gene VEGFA and hypertensive disorder.